雅虎香港 搜尋

搜尋結果

  1. solution. The type and amount of viral antigens contained in VAXIGRIPfi conform to the current requirements of the World Health Organization (WHO). (1) The strains for the 2011-2012 season are: A/California/7/2009 (H1N1)-like strain, A/Perth/16/2009 (H3N2

  2. This quadrivalent formulation of Vaxigrip contains two A and two B influenza strains (VaxigripTetra), and has a similar immunogenicity and safety profile to the trivalent formulation while offering broader protection due to the addition of the second influenza B strain.

    • Margaret Haugh, Viviane Gresset-Bourgeois, Bérengère Macabeo, Anne Woods, Sandrine I. Samson
    • 2017
  3. 季節性流感疫苗成分. 院舍防疫注射計劃在2015/16年度提供的疫苗包括以下成分: - 類甲型/加利福利亞/ 7/ 2009 (H1N1)pdm09病毒. - 類甲型/瑞士/9715293/2013 (H3N2) 病毒. - 類乙型/布吉/3073/2013病毒. - 類乙型/布利斯本/60/2008病毒. 院舍防疫注射計劃2015/16採用的是滅活流感疫苗。 建議劑量. 9歲或以上人士,每年都要接種一劑季節性流感疫苗。 為確保對季節性流感產生足夠的免疫力,凡9歲以下從未接種過季節性流感疫苗的兒童,建議應接種兩劑季節性流感疫苗,而兩劑疫苗的接種時間應至少相隔四個星期。 在2014/15年度或以前曾接種季節性流感疫苗的9歲以下兒童,在2015/16年度只需接種一劑疫苗。

  4. Vaxigrip/Vaxigrip Tetra Vaxigrip and its quadrivalent formulation Vaxigrip Tetra are split virus inactivated vaccines made by Sanofi Pasteur in Europe. Vaxigrip provides immune responses to three influenza strains and VaxigripTetra adds

  5. 2018年3月8日 · PMCID: PMC5874655. PMID: 29518013. Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults. Emanuele Montomoli, 1,2 Alessandro Torelli, 1,3 Ilaria Manini, 2 and Elena Gianchecchi 1,*

    • Emanuele Montomoli, Alessandro Torelli, Ilaria Manini, Elena Gianchecchi
    • 10.3390/vaccines6010014
    • 2018
    • Vaccines (Basel). 2018 Mar; 6(1): 14.
  6. 本網頁資料僅供參考,如有疑問或錯誤請仍依廠商資料為主。. 醫令碼. 3683D. 健保碼. K001036206. 商品名. VAXIGRIP TETRA 0.5ML (3歲以上) (公費) 藥品許可證. 衛署菌疫輸字第000453號.

  7. IIV4 builds on the well-established record of the trivalent split-virion influenza vaccine (Vaxigrip®). Areas covered: This literature review summarizes the rationale for developing quadrivalent influenza vaccines and discusses the phase III clinical trial results supporting the immunogenicity, safety, and tolerability of IIV4.